<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; frontier</title>
	<atom:link href="http://www.tapanray.in/tag/frontier/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>India&#8217;s Pharmacy Frontier: Blurring Lines and Battling for Balance</title>
		<link>http://www.tapanray.in/indias-pharmacy-frontier-blurring-lines-and-battling-for-balance/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indias-pharmacy-frontier-blurring-lines-and-battling-for-balance</link>
		<comments>http://www.tapanray.in/indias-pharmacy-frontier-blurring-lines-and-battling-for-balance/#comments</comments>
		<pubDate>Fri, 20 Jun 2025 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[e-pharmacy]]></category>
		<category><![CDATA[frontier]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[online]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[retail]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10921</guid>
		<description><![CDATA[As we witness, India&#8217;s pharmaceutical landscape is undergoing a profound transformation, driven by technological advancements and shifting consumer preferences. The traditional brick-and-mortar retail pharmacy, a familiar fixture in every neighborhood, now faces a formidable challenger: the burgeoning online pharmacy sector. &#8230; <a href="http://www.tapanray.in/indias-pharmacy-frontier-blurring-lines-and-battling-for-balance/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indias-pharmacy-frontier-blurring-lines-and-battling-for-balance/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biosimilar Drugs: First Indian Foot Print In An Uncharted Frontier</title>
		<link>http://www.tapanray.in/biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier</link>
		<comments>http://www.tapanray.in/biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier/#comments</comments>
		<pubDate>Mon, 04 Apr 2016 00:00:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Boehringer Ingelheim]]></category>
		<category><![CDATA[Challenging]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Eli Lilly]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[frontier]]></category>
		<category><![CDATA[Glargine]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insulin]]></category>
		<category><![CDATA[Interchangeability]]></category>
		<category><![CDATA[Japan]]></category>
		<category><![CDATA[label]]></category>
		<category><![CDATA[Lantus]]></category>
		<category><![CDATA[lantus XR]]></category>
		<category><![CDATA[name]]></category>
		<category><![CDATA[non-proprietory]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[original. substitution]]></category>
		<category><![CDATA[pen]]></category>
		<category><![CDATA[pre-filled]]></category>
		<category><![CDATA[prescriber]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[skepticism]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Toujeo]]></category>
		<category><![CDATA[uncharted]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7578</guid>
		<description><![CDATA[A homegrown Indian biologic manufacturer is now about to leave behind its first foot-print, with a ‘made in India’ biosimilar drug, in one of the largest pharma market of the world. This was indeed an uncharted frontier, and a dream &#8230; <a href="http://www.tapanray.in/biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Conundrum of Stringent IPR Regime in India: Responsible Pricing still remains ‘The Final Frontier’</title>
		<link>http://www.tapanray.in/the-conundrum-of-stringent-ipr-regime-in-india-responsible-pricing-still-remains-the-final-frontier/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-conundrum-of-stringent-ipr-regime-in-india-responsible-pricing-still-remains-the-final-frontier</link>
		<comments>http://www.tapanray.in/the-conundrum-of-stringent-ipr-regime-in-india-responsible-pricing-still-remains-the-final-frontier/#comments</comments>
		<pubDate>Mon, 26 Nov 2012 00:00:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[conundrum]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[final]]></category>
		<category><![CDATA[frontier]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[regime]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[responsible]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[stringent]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1063</guid>
		<description><![CDATA[In his management classic named, ‘The Practice of management’, published in 1954, the universal management guru Peter Drucker postulated that any successful business is driven by only the following two fundamental functions: Marketing Innovation …and all the rests are costs. &#8230; <a href="http://www.tapanray.in/the-conundrum-of-stringent-ipr-regime-in-india-responsible-pricing-still-remains-the-final-frontier/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-conundrum-of-stringent-ipr-regime-in-india-responsible-pricing-still-remains-the-final-frontier/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
